158 related articles for article (PubMed ID: 35512184)
1. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma.
Cherng HJ; Sun R; Sugg B; Irwin R; Yang H; Le CC; Deng Q; Fayad L; Fowler NH; Parmar S; Steiner R; Hagemeister F; Nair R; Lee HJ; Rodriguez M; Samaniego F; Iyer SP; Flowers CR; Wang L; Nastoupil LJ; Neelapu SS; Ahmed S; Strati P; Green MR; Westin J
Blood; 2022 Aug; 140(5):504-515. PubMed ID: 35512184
[TBL] [Abstract][Full Text] [Related]
2. Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy.
Zou H; Liu W; Wang X; Wang Y; Wang C; Qiu C; Liu H; Shan D; Xie T; Huang W; Sui W; Yi S; An G; Xu Y; Ma T; Wang J; Qiu L; Zou D
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38443094
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
4. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
5. Cell-Free DNA Dynamic Concentration and Other Variables Are Predictors of Early Progression after Chimeric Antigen Receptor T Cell Therapy in Patients with Diffuse Large B Cell Lymphoma.
Bastos-Oreiro M; Sanz-Villanueva L; Muñiz P; Bailén R; Chicano M; Oarbeskoa G; Gómez I; Gutiérrez A; Iglesia I; Carbonell D; Diaz-Crespo FJ; Menarguez J; Diez-Martín JL; Kwon M; Buño I; Martínez-Laperche C
Transplant Cell Ther; 2023 Jul; 29(7):472.e1-472.e4. PubMed ID: 36921917
[TBL] [Abstract][Full Text] [Related]
6. Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy.
Wang C; Shi F; Liu Y; Zhang Y; Dong L; Li X; Tong C; Wang Y; Su L; Nie J; Han W
J Hematol Oncol; 2021 Jul; 14(1):106. PubMed ID: 34225766
[TBL] [Abstract][Full Text] [Related]
7. Assessing CAR T-Cell Therapy Response Using Genome-Wide Sequencing of Cell-Free DNA in Patients With B-Cell Lymphomas.
Goodman AM; Holden KA; Jeong AR; Kim L; Fitzgerald KD; Almasri E; McLennan G; Eisenberg M; Jahromi AH; Hoh C; Hurley M; Mulroney C; Tzachanis D; Ball ED; Jensen TJ; Kurzrock R
Transplant Cell Ther; 2022 Jan; 28(1):30.e1-30.e7. PubMed ID: 34655803
[TBL] [Abstract][Full Text] [Related]
8. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
9. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
[TBL] [Abstract][Full Text] [Related]
10. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.
Rejeski K; Perez A; Iacoboni G; Penack O; Bücklein V; Jentzsch L; Mougiakakos D; Johnson G; Arciola B; Carpio C; Blumenberg V; Hoster E; Bullinger L; Locke FL; von Bergwelt-Baildon M; Mackensen A; Bethge W; Barba P; Jain MD; Subklewe M
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580927
[TBL] [Abstract][Full Text] [Related]
11. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.
Lin JK; Muffly LS; Spinner MA; Barnes JI; Owens DK; Goldhaber-Fiebert JD
J Clin Oncol; 2019 Aug; 37(24):2105-2119. PubMed ID: 31157579
[TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
Schuster SJ; Svoboda J; Chong EA; Nasta SD; Mato AR; Anak Ö; Brogdon JL; Pruteanu-Malinici I; Bhoj V; Landsburg D; Wasik M; Levine BL; Lacey SF; Melenhorst JJ; Porter DL; June CH
N Engl J Med; 2017 Dec; 377(26):2545-2554. PubMed ID: 29226764
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
Hay KA; Gauthier J; Hirayama AV; Voutsinas JM; Wu Q; Li D; Gooley TA; Cherian S; Chen X; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Schoch G; Chapuis AG; Till BG; Kiem HP; Ramos JD; Shadman M; Cassaday RD; Acharya UH; Riddell SR; Maloney DG; Turtle CJ
Blood; 2019 Apr; 133(15):1652-1663. PubMed ID: 30728140
[TBL] [Abstract][Full Text] [Related]
14. Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells.
Xu Q; Xue L; An F; Xu H; Wang L; Geng L; Zhang X; Song K; Yao W; Wan X; Tong J; Liu H; Liu X; Zhu X; Zhai Z; Sun Z; Wang X
Front Immunol; 2022; 13():879030. PubMed ID: 35558072
[TBL] [Abstract][Full Text] [Related]
15. CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure.
Caballero AC; Escribà-Garcia L; Alvarez-Fernández C; Briones J
Front Immunol; 2022; 13():904497. PubMed ID: 35874685
[TBL] [Abstract][Full Text] [Related]
16. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
Kochenderfer JN; Somerville RPT; Lu T; Yang JC; Sherry RM; Feldman SA; McIntyre L; Bot A; Rossi J; Lam N; Rosenberg SA
Mol Ther; 2017 Oct; 25(10):2245-2253. PubMed ID: 28803861
[TBL] [Abstract][Full Text] [Related]
17. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.
Pinnix CC; Gunther JR; Dabaja BS; Strati P; Fang P; Hawkins MC; Adkins S; Westin J; Ahmed S; Fayad L; Lee HJ; Nair R; Steiner RE; Iyer SP; Rodriguez MA; Wang M; Flowers C; Neelapu SS; Nastoupil LJ
Blood Adv; 2020 Jul; 4(13):2871-2883. PubMed ID: 32589728
[TBL] [Abstract][Full Text] [Related]
18. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
Sesques P; Ferrant E; Safar V; Wallet F; Tordo J; Dhomps A; Karlin L; Brisou G; Vercasson M; Hospital-Gustem C; Schwiertz V; Ranchon F; Rioufol C; Choquet M; Sujobert P; Ghergus D; Bouafia F; Golfier C; Lequeu H; Lazareth A; Novelli S; Devic P; Traverse Glehen A; Viel S; Venet F; Mialou V; Hequet O; Chauchet A; Arkam Y; Nicolas-Virelizier E; Peyrade F; Cavalieri D; Ader F; Ghesquières H; Salles G; Bachy E
Am J Hematol; 2020 Nov; 95(11):1324-1333. PubMed ID: 32744738
[TBL] [Abstract][Full Text] [Related]
19. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany.
Bethge WA; Martus P; Schmitt M; Holtick U; Subklewe M; von Tresckow B; Ayuk F; Wagner-Drouet EM; Wulf GG; Marks R; Penack O; Schnetzke U; Koenecke C; von Bonin M; Stelljes M; Glass B; Baldus CD; Vucinic V; Mougiakakos D; Topp M; Fante MA; Schroers R; Bayir L; Borchmann P; Buecklein V; Hasenkamp J; Hanoun C; Thomas S; Beelen DW; Lengerke C; Kroeger N; Dreger P
Blood; 2022 Jul; 140(4):349-358. PubMed ID: 35316325
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
